Hepatitis B virus (HBV)
3 infection is a major health problem worldwide. It is estimated that more than 1 million persons in the United States are chronic HBV carriers and are potentially infectious to others. In addition, HBV chronic carriers are at high risk for liver cirrhosis and hepatocellular carcinoma (1) (2) (3) . Identification of HBV carrier status in pregnant women and blood donors is critical to eliminating the transmission of HBV through blood transfusion and drastically decreasing the rate of infant infection through maternal transmission (4 -6 ) .
Hepatitis B surface antigen (HBsAg) is an HBV serologic marker that plays a major role in the diagnosis of HBV infection. A new-generation chemiluminescent HBsAg assay performed on the Immulite 2000 [Diagnostics Product Corporation (DPC)] measures HBsAg with a method that involves 2 steps: initial screening and confirmation neutralization. We observed that a relatively high percentage of weakly reactive (WR) samples did not pass the confirmation neutralization step and therefore investigated these results.
Material and Methods
We analyzed samples sent to the Bellevue Hospital laboratory for routine assessment of HBV infectivity status. Beginning in May 2003, we used the Immulite 2000 assay (DPC) to measure HBsAg. We investigated the performance of the assay during 3 different 1-month time periods, which corresponded to the use of 3 different lots of reagent. During each 1-month period for each reagent lot, we collected HBsAg sample data from all HBsAg tests performed for the Bellevue Hospital patient population. We also calculated the positive detection rates of HBsAg by the Immulite 2000 assay and the historical positive rate of detection by the Abbott Auszyme enzyme immunoassay in the Bellevue patient population (same data collection procedure as for Immulite 2000 assay) and used 2 analysis to compare the results.
The HBsAg qualitative assay requires 2 incubation steps and a total reaction time of 65 min. Patient results were reported as reactive [sample signal/assay cutoff (S/C) index Ն1.00] or nonreactive (S/C ratio Ͻ1.00). The DPC protocol requires that samples deemed reactive must be repeated in duplicate. If the S/C ratios of 2 replicates are both Ͻ1.00, the result of this sample is reported as nonreactive. If the S/C of at least 1 of the 2 replicates is Ն1.00, the sample is considered reactive, and the result must be confirmed by an HBsAg neutralization test, in which the percentage of HBsAg signal reduction in the presence of antibodies against HBsAg (aHBs) is measured (7 ) . The DPC HBsAg confirmation protocol requires a signal reduction of Ն50% after neutralization. If the signal reduction is Ͻ50%, then the sample is considered negative for HBV (7, 8 ) .
The Abbott Auszyme enzyme immunoassay is a semimanual procedure that involves 2 incubation steps at 2 different temperatures (reaction at 40°C and color development at room temperature). The cutoff value of each run is calculated from a formula based on the negative controls from that run (9 ) .
Qualitative assays for aHBs, total antibodies against HB core antigen (aHBcT), and IgM antibodies against HB core antigen (aHBcIgM) were run on the DPC Immulite 2000. The DPC-defined criteria for positive results of these assays are as follow: aHBs Ն11.0 mIU/mL (10, 11 ) , aHBcIgM Ն11.0 IU/mL (12 ) , and aHBcT cutoff/signal Ն1.15 (13 ) . We used 2 statistical analysis of reactive rates among different lots (14, 15 ) .
We used the Roche COBAS Amplicor HBV Monitor test (Ver. 2.0) to detect HBV viral DNA (16, 17 ) . Although the quantitative detection limit is Ն200 copies/mL, qualitatively the detection limit goes to zero. A sample with a result of 1 to 199 copies/mL is reported as "Ͻ200 copies"; a sample with 0 copies is reported as "no HBV DNA detected".
Results
Our initial results are shown in Table 1 . Samples tested with reagent lots A and B on the DPC Immulite 2000 assay yielded a fairly high percentage of initially reactive samples. Statistical analysis indicated that the initial positive rate of the DPC assay was significantly different from the initial positive rate of the Abbott assay, particularly in the case of lots A and B. After we performed the confirmation step, up to 70% of the initially reactive samples had Ͻ50% neutralization activity.
We randomly selected ϳ200 patient samples with initial reactive HBsAg results (S/C ratio Ն1.00) from lots A and B for the confirmation outcome study. Samples with unconfirmed neutralization Ͻ50% and samples with confirmed neutralization (Ն50%) were grouped separately. The relationship between patient S/C result and neutralization result is illustrated in Fig. 1 . It is clear that the confirmation rate correlates with the S/C ratio: the higher the ratio, the greater likelihood of being confirmed by neutralization. In group 1, 98% of samples had S/C ratios Ͻ2.5, whereas group 2 contained all of the samples with S/C ratios Ͼ10. The high initial positivity rate and the subsequent failure at the confirmation step for a significant portion of the initial positives led us to question the clinical significance of these results and led to further investigation. To get a better understanding of the true nature of these WR samples, we used HBV viral load and other HBV serologic markers to judge the HBV infectious status.
hbv dna load test
Patient samples (n ϭ 127) with WR HBsAg results (S/C ratio Յ2.5) measured on the DPC Immulite 2000 assay with reagents from any 1 of the 3 lots were randomly selected and tested for the viral load and other serologic HBV markers. Among the 127 samples, 38 had Ն50% neutralization activity and the other 89 had Ͻ50% neutralization activity.
The PCR results indicated that 83 of the 89 WR samples with Ͻ50% neutralization activity (93%) had no detectable HBV DNA (zero copies); 6 of the 89 had low DNA (up to 9000 copies/mL). The serologic profiles of the 6 samples with detectable HBV DNA are shown in Table 2 . One sample had positive aHBcIgM (45% HBsAg confirmation and negative aHBs), suggesting early acute-phase infection; 2 samples had positive aHBcT and negative aHBs, suggesting either early or chronic infection; and 3 had negative aHBs, aHBcT, and aHBcIgM. These 3 samples could indicate a very early stage of infection, in which case HBsAg reactivity would be low, or infection with (an) HBsAg mutant strain(s) that led to neutralization failure (18 ) . For 1 of the 6 samples (sample 3, which was negative for aHBs, HBsAg, and aHBcT), the patient had follow-up tests ordered 1 year later. The follow-up indicated that both HBsAg and aHBs were still negative. However, the lack of aHBcT data made it difficult to differentiate the likely cause of the original positive HBV viral load result.
In the group of 38 WR samples that did have Ն50% neutralization in the confirmatory step, 22 samples (58%) had no detectable DNA (zero copies), and 16 samples had detectable HBV DNA. Among this group of WR samples, the correlation between the DNA copy number and the quantitative index of the HBsAg serologic result was poor (Fig. 2) .
The 22 HBV DNA-negative samples could be divided into 5 groups based on available serologic markers other than HBsAg (Table 3) . Because group 2 samples had positive aHBs and negative aHBcT, suggesting previous immunization, their Ն50% neutralization HBsAg results were most likely false positives. The follow-up results available for samples from groups 1 and 4 suggested that at least 2 samples had false-positive HBsAg results (follow-up with negative results for both HBsAg and aHBs). Furthermore, 1 group 1 sample from a hemodialysis patient was highly likely to be false positive because 12 subsequent HBsAg follow-up tests (1 per month) were all negative.
The serologic profile of aHBs Ϫ /aHBcT ϩ /aHBcM Ϫ for group 5 samples indicated that the HBsAg-positive results were highly likely to be true positives despite the lack of detectable HBV DNA in these samples. One of the 6 samples had a follow-up result that repeated as aHBcT ϩ /HBsAg ϩ , which provided further evidence for the likely true HBsAg positivity of the original patient sample.
Discussion
Our current study (Fig. 3) and previously published data indicate that although the Immulite 2000 HBsAg assay has HBsAg detection rates similar to those of the Abbott Auzyme and Bayer Centaur (19 ) , the specificity of the Immulite 2000 at the initial run is not as high as the other 2 assays. The occurrence of a high number of initially positive results that are not confirmed by the neutralization step is likely related to the inherent poor separation between signal and background noise of this assay. We found that as a consequence of this poor specificity, the rate of initially positive samples was 1.5-to 3.5-fold higher than for the Abbott assay (see Table 1 ). Although we observed this situation over multiple reagent lots during the last 3 years, we also found that the quality of the assay reagent has improved (see lot C in Table 1 ). However, a reasonable and accurate report format is still needed for the ϳ1% of samples that are WR, regardless of whether they pass confirmation criteria. The Immulite 2000 assay instructions state that, "the patient appears to not be infected with HBV" if the neutralization is Ͻ50%, whereas any sample with neutralization Ն50% should be reported as "confirmed reactive for HBsAg" (8 ) . Our results, however, suggest that this approach may lead to both falsepositive and false-negative results and that, therefore, a more careful and thorough protocol is needed to deal with this issue.
To avoid the reporting of false-negative HBsAg results, we suggest that any sample, from any manufacturer, with a low-positive result that does not pass the assay's confirmation test not be designated "nonreactive" until other HBV serologic markers are measured to provide a clearer picture of the patient's status (Fig. 4) . For these samples, laboratories should consider reflex testing to aHBcT, aHBs, and aHBcIgM, if these tests were not ordered by the physician together with the HBsAg test, and review by the laboratory director.
In a similar vein, our data also indicate that at least some of the samples (6 of the 22) that were WR (S/C ratios, 1.00 -2.50) and did pass neutralization criteria for positive results did not have evidence of HBV infection (Table 3 ). This finding is understandable because the impact of the inherent high CV (ϳ10%) and poor separation between signal and noise of this assay (19 ) can give poor separation between true negatives and false positives.
Although the DPC assay instructions advise laboratories to rely entirely on the neutralization result to decide the HBsAg outcome, our results suggest that further testing is needed before WR samples are reported as "confirmed HBsAg reactive". Again, we would recommend that other HBV serologic markers be tested and that final results reported as confirmed HBsAg reactive only if the sample is also positive for aHbcT and/or aHbcIgM. Otherwise, the test should be repeated in 2 weeks (Fig. 4) . This approach is similar to some other test procedures recommended by the CDC. In the guidelines for laboratory testing and result reporting of HCV antibody, the CDC recommends that a reflex test be performed before HCV positives with low S/C ratios are reported (20 ) .
Although we investigated only the DPC Immulite assay, we suspect that similar low positive results with questionable status might occur with other HBsAg assays, and we recommend study of the issue by each laboratory.
In conclusion, our analysis of the performance of the DPC Immulite 2000 chemiluminescent HBsAg test at Bellevue Hospital indicates that samples identified by this assay as WR (S/C ratios, 1.00 -2.50) need additional testing and review, regardless of neutralization status. Laboratories should establish HBV test panel(s) to allow the reflex test(s) such as aHBcT and aHBcIgM to be performed in these cases.
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